Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from Georgetown University.
2458 articles by Ned Pagliarulo
-
Novavax gets a lifeline with Sanofi vaccine pact
May 10, 2024 -
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
May 9, 2024 -
Verve moves forward with backup base editing therapy
May 7, 2024 -
Bluebird, Vertex prep for first commercial use of sickle cell gene therapies
May 6, 2024 -
Why selling to Novartis made sense for Mariana
May 3, 2024 -
BridgeBio spinout launches with $200M for KRAS cancer drugs
May 2, 2024 -
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
May 1, 2024 -
Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb
April 30, 2024 -
Prime gets FDA green light to begin first trial test of ‘prime editing’
April 29, 2024 -
Bristol Myers to cut 6% of workforce, trim drug pipeline
April 25, 2024 -
Moderna turns to AI to change how its employees work
April 24, 2024 -
Novartis raises forecasts as top drug sales beat Wall Street estimates
April 23, 2024 -
Bristol Myers taps startup to boost cell therapy production
April 22, 2024 -
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
April 18, 2024 -
J&J sees mixed performance from new multiple myeloma drugs
April 16, 2024 -
Ultragenyx says Angelman therapy is working, but safety questions remain
April 15, 2024 -
FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use
April 5, 2024 -
Merck puts KRAS cancer drug competitor to the test
April 4, 2024 -
Verve pauses base editing trial, shifts strategy after treatment side effect
April 2, 2024 -
Gilead bets on Xilio cancer drug as biotech restructures
March 28, 2024 -
Stoke shares surge on updated results for Dravet drug
March 26, 2024 -
Novo to acquire heart failure drug in $1B deal for Cardior
March 25, 2024 -
With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease
Feb. 29, 2024 -
Janux shares triple on early cancer immunotherapy data
Feb. 27, 2024 -
Minerva schizophrenia drug rejected by FDA
Feb. 27, 2024